Downloads
Slow and uneven clinical trial recruitment is one of the greatest obstacles to developing treatments for Alzheimer’s disease. Limited evidence on effective recruitment strategies has made it difficult to identify opportunities for improvement.
The USC Clinical Trial Recruitment Lab (CTRL), which was created to close this knowledge gap, convened leaders from across the U.S. clinical trial ecosystem to share scalable, evidence-based solutions that can speed enrollment and ensure that trials reflect the communities most affected by Alzheimer’s. A recurring theme of this symposium was the potential of new technologies, improved diagnostics and targeted engagement to accelerate and enhance recruitment.
A new report highlights key takeaways from the event, including:
- The value of prevention: A keynote address from Schaeffer Institute Founding Director Dana Goldman demonstrated how early intervention and treatment can reduce Alzheimer’s staggering economic toll.
- What works: An expert panel shared examples of successful recruitment approaches, including how technology can better connect patients to trials.
- The power of AI: Researchers pitched AI-driven pilots to improve recruitment efficiency and inclusiveness.
More information about the event and the full recording are available here.
About CTRL
CTRL pilots, evaluates, and disseminates innovative recruitment strategies to improve access and representation in clinical trials. It is a joint initiative of the USC Schaeffer Center for Health Policy & Economics and the USC Epstein Family Alzheimer’s Therapeutic Research Institute.
